The comparative safety of first-line conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) used for the treatment of rheumatoid arthritis: protocol for a multi-database real-world cohort study

30/01/2020
30/01/2020
EU PAS number:
EUPAS33214
Study
Ongoing
Documents
Study protocol
Initial protocol
English (306.42 KB - PDF) View document
Study results
Study report
Other information
ENCePP Seal
Signed checklist for study protocols
English (217.19 KB - PDF) View document